Literature DB >> 10894351

Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors.

J L Ferrara1.   

Abstract

The pathogenesis of acute graft versus host disease (GVHD) is multistep process. This review considers acute GVHD in three sequential steps: conditioning regimen, donor T cell activation, and effector mechanisms. In step one, the conditioning regimen simultaneously damages and activates host tissues, amplifying antigen presentation to allogeneic donor T cells. In step two, donor T cells, activated by host alloantigens, proliferate and secrete a variety of cytokines. Type 1 cytokines (interleukin-2 and interferon-y) are critical for acute GVHD, but several regulatory mechanisms of tissue damage include inflammatory cytokines and cytolytic cellular effectors. The gastrointestinal (GI) tract is a principal target organ because damage to the GI mucosa can release inflammatory mediators such as endotoxin that amplify systemic disease. The inflammatory processes of acute GVHD can be considered as a distortion of the cellular responses to viral and bacterial infections. Cell-mediated toxicity is critical to other GVHD target organs, particularly the liver, where Fas-mediated injury predominates. The cytolytic pathways (e.g., perforin) clearly intensify acute GVHD, although they are not necessary for systemic disease in several model systems. Many of these insights come from animal models using mutant mouse strains that can clarify the role of individual proteins or cell types in the disease process. These insights should allow the testing of new classes of drugs and inhibitors in clinical bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10894351     DOI: 10.1089/15258160050079407

Source DB:  PubMed          Journal:  J Hematother Stem Cell Res        ISSN: 1525-8165


  36 in total

1.  Impaired regulatory T cell reconstitution in patients with acute graft-versus-host disease and cytomegalovirus infection after allogeneic bone marrow transplantation.

Authors:  Alain M Ngoma; Kazuhiko Ikeda; Yuko Hashimoto; Kazuhiro Mochizuki; Hiroshi Takahashi; Hideki Sano; Hayato Matsumoto; Hideyoshi Noji; Syunnichi Saito; Atsushi Kikuta; Kazuei Ogawa; Mikio Ohtsuka; Masafumi Abe; Kenneth E Nollet; Hitoshi Ohto
Journal:  Int J Hematol       Date:  2011-12-14       Impact factor: 2.490

2.  Customized molecular phenotyping by quantitative gene expression and pattern recognition analysis.

Authors:  Shreeram Akilesh; Daniel J Shaffer; Derry Roopenian
Journal:  Genome Res       Date:  2003-07       Impact factor: 9.043

3.  Posterior reversible encephalopathy syndrome in infection, sepsis, and shock.

Authors:  W S Bartynski; J F Boardman; Z R Zeigler; R K Shadduck; J Lister
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

4.  Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoeitic malignancies and marrow conditions after allogeneic bone marrow transplantation.

Authors:  Walter S Bartynski; Zella R Zeigler; Richard K Shadduck; John Lister
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

5.  Expression of CD27 on peripheral CD4+ T-lymphocytes correlates with the development of severe acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Hitoshi Yoshida; Tetsuo Maeda; Jun Ishikawa; Shinya Inoue; Hitomi Matsunaga; Satoru Kosugi; Masamichi Shiraga; Kenji Oritani; Yuzuru Kanakura; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

6.  Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity.

Authors:  Kai Sun; Danice E C Wilkins; Miriam R Anver; Thomas J Sayers; Angela Panoskaltsis-Mortari; Bruce R Blazar; Lisbeth A Welniak; William J Murphy
Journal:  Blood       Date:  2005-06-16       Impact factor: 22.113

Review 7.  Graft-versus-host disease and immunosuppression.

Authors:  Neena Kapoor
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 8.  Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-10       Impact factor: 3.825

9.  Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity.

Authors:  Mohammad S Hossain; David L Jaye; Brian P Pollack; Alton B Farris; Malefa L Tselanyane; Ebenezer David; John D Roback; Andrew T Gewirtz; Edmund K Waller
Journal:  J Immunol       Date:  2011-10-17       Impact factor: 5.422

10.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Authors:  Howard M Shulman; Diana M Cardona; Joel K Greenson; Sangeeta Hingorani; Thomas Horn; Elisabeth Huber; Andreas Kreft; Thomas Longerich; Thomas Morton; David Myerson; Victor G Prieto; Avi Rosenberg; Nathaniel Treister; Kay Washington; Mirjana Ziemer; Steven Z Pavletic; Stephanie J Lee; Mary E D Flowers; Kirk R Schultz; Madan Jagasia; Paul J Martin; Georgia B Vogelsang; David E Kleiner
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-29       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.